See more : New York City REIT, Inc. (NYC) Income Statement Analysis – Financial Results
Complete financial analysis of Poxel S.A. (0RA2.L) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Poxel S.A., a leading company in the Biotechnology industry within the Healthcare sector.
- Mako Gold Limited (MKG.AX) Income Statement Analysis – Financial Results
- Dhampur Bio Organics Limited (DBOL.NS) Income Statement Analysis – Financial Results
- Ferroglobe PLC (GSM) Income Statement Analysis – Financial Results
- Churchill Capital Corp IX Unit (CCIXU) Income Statement Analysis – Financial Results
- Koa Shoji Holdings Co.,Ltd. (9273.T) Income Statement Analysis – Financial Results
Poxel S.A. (0RA2.L)
About Poxel S.A.
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH). Poxel S.A. has a licensing agreement with Enyo Pharma S.A.S. for the development of farnesoid X receptor that is in Phase 2a study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial pyruvate carrier inhibitor, which is in a phase I clinical trial for the treatment of NASH. The company was incorporated in 2009 and is headquartered in Lyon, France.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.98M | 674.00K | 13.40M | 6.81M | 26.56M | 74.61M | 5.29M | 70.27K | 59.65K | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.98M | 672.00K | 59.00K | 551.00K | 0.00 | 0.00 | 0.00 | 0.00 | 25.19K | 23.21K | 15.60K | 0.00 | 0.00 |
| Gross Profit | 1.00K | 2.00K | 13.34M | 6.26M | 26.56M | 74.61M | 5.29M | 70.27K | 34.46K | -23.21K | -15.60K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.05% | 0.30% | 99.56% | 91.90% | 100.00% | 100.00% | 100.00% | 100.00% | 57.77% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 20.95M | 13.94M | 27.48M | 29.24M | 44.55M | 58.09M | 24.10M | 20.92M | 9.24M | 7.00M | 9.08M | 8.70M | 10.37M |
| General & Administrative | 5.03M | 4.44M | 10.63M | 9.94M | 7.41M | 4.49M | 3.45M | 3.83M | 2.68M | 941.58K | 616.97K | 555.83K | 788.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 519.85K | 20.67K | 15.67K | 0.00 | 0.00 |
| SG&A | 5.03M | 4.44M | 10.63M | 9.94M | 7.41M | 4.49M | 3.45M | 3.83M | 2.68M | 941.58K | 616.97K | 555.83K | 788.00K |
| Other Expenses | 2.79M | 3.51M | -2.31M | -2.52M | -733.00K | -512.00K | -353.31K | -398.37K | -137.06K | -1.04M | -2.43M | -2.13M | -2.47M |
| Operating Expenses | 28.77M | 21.89M | 35.80M | 36.65M | 51.23M | 62.07M | 27.19M | 24.35M | 11.78M | 6.90M | 7.27M | 7.12M | 8.68M |
| Cost & Expenses | 30.75M | 22.56M | 35.86M | 36.65M | 51.23M | 62.07M | 27.19M | 24.35M | 11.78M | 6.90M | 7.27M | 7.12M | 8.68M |
| Interest Income | 0.00 | 17.00K | 48.00K | 382.00K | 222.00K | 368.00K | 63.50K | 287.12K | 293.94K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 6.15M | 3.81M | 2.95M | 1.67M | 185.00K | 28.00K | 46.51K | 479.57K | 856.56K | 371.38K | 13.18M | 18.71K | -57.60K |
| Depreciation & Amortization | 17.20M | 555.00K | 556.00K | 551.00K | 424.00K | 62.00K | 37.90K | 32.01K | 22.98K | 12.34K | 15.39K | 15.34K | 13.68K |
| EBITDA | -12.17M | -28.02M | -22.52M | -29.72M | -24.59M | -2.81M | -21.87M | -23.15M | -11.31M | -15.64M | -23.32M | -9.40M | -11.32M |
| EBITDA Ratio | -614.49% | -3,203.26% | -157.30% | -453.78% | -90.97% | 16.89% | -419.91% | -34,115.64% | -19,255.19% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -28.76M | -21.89M | -22.46M | -29.85M | -24.67M | 12.54M | -21.90M | -24.28M | -11.72M | -6.90M | -7.27M | -7.12M | -8.68M |
| Operating Income Ratio | -1,451.99% | -3,247.77% | -167.66% | -438.54% | -92.90% | 16.81% | -414.02% | -34,558.20% | -19,649.54% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -6.32M | -9.51M | -1.30M | -1.98M | -1.07M | 13.29M | -395.11K | -1.30M | -905.06K | -7.19M | -13.18M | -18.71K | 57.60K |
| Income Before Tax | -35.09M | -31.40M | -23.76M | -31.82M | -25.74M | 13.60M | -22.30M | -24.48M | -12.24M | -14.08M | -20.45M | -7.14M | -8.62M |
| Income Before Tax Ratio | -1,771.23% | -4,658.16% | -177.35% | -467.56% | -96.93% | 18.23% | -421.50% | -34,843.71% | -20,521.40% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 2.00K | 2.00K | 2.00K | 36.00K | 1.00K | 77.00K | 395.93K | 200.62K | -124.24K | 72.02K | 13.18M | 18.71K | -57.60K |
| Net Income | -35.09M | -31.40M | -23.76M | -31.86M | -25.74M | 13.53M | -22.69M | -24.48M | -12.24M | -14.08M | -20.45M | -7.14M | -8.62M |
| Net Income Ratio | -1,771.33% | -4,658.46% | -177.37% | -468.09% | -96.93% | 18.13% | -428.99% | -34,843.71% | -20,521.40% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.91 | -1.08 | -0.83 | -1.16 | -0.99 | 0.54 | -0.99 | -1.16 | -0.68 | -0.80 | -1.16 | -0.72 | -0.86 |
| EPS Diluted | -0.91 | -1.08 | -0.83 | -1.16 | -0.99 | 0.54 | -0.99 | -1.16 | -0.68 | -0.80 | -1.16 | -0.72 | -0.86 |
| Weighted Avg Shares Out | 38.60M | 29.08M | 28.64M | 27.53M | 25.94M | 24.83M | 23.03M | 21.07M | 17.92M | 17.63M | 17.63M | 9.98M | 9.98M |
| Weighted Avg Shares Out (Dil) | 38.60M | 29.08M | 28.64M | 27.53M | 25.94M | 24.83M | 23.03M | 21.07M | 17.92M | 17.63M | 17.63M | 9.98M | 9.98M |
Source: https://incomestatements.info
Category: Stock Reports